Calidi Biotherapeutics (CLDI) News Today $0.46 0.00 (-0.43%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.46 0.00 (-0.22%) As of 04/17/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Calidi announces FDA clearance of IND application for CLD-201April 18 at 9:34 PM | markets.businessinsider.comCalidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid TumorsApril 17 at 10:25 PM | markets.businessinsider.comCalidi appoints Guy Travis Clifton as CMO, Consultant, AdvisorApril 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and AdvisorApril 10, 2025 | finance.yahoo.comCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational HighlightsMarch 31, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementMarch 31, 2025 | globenewswire.comCalidi Biotherapeutics Provides Update On Phase 1 Trial Of CLD-101 For Recurrent GliomaMarch 29, 2025 | nasdaq.comCalidi prices 3.33M shares at 65c in registered direct offeringMarch 29, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementMarch 28, 2025 | globenewswire.comCalidi, City of Hope provide update on Phase 1 trial with CLD-101March 27, 2025 | markets.businessinsider.comIBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy PlatformMarch 11, 2025 | finance.yahoo.comCalidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy PlatformMarch 11, 2025 | theglobeandmail.comCalidi announces ability to deliver transient gene therapy to tumorsMarch 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic PlatformMarch 10, 2025 | globenewswire.comCalidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVFebruary 28, 2025 | finanznachrichten.deCalidi commences recruitment for multiple dose CLD-101 trialFebruary 24, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University HospitalFebruary 24, 2025 | globenewswire.comCalidi Biotherapeutics expands stock offering capacityFebruary 5, 2025 | msn.comJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5January 30, 2025 | markets.businessinsider.comCLDI Stock Plummets to 52-Week Low at $0.6 Amid Market TurbulenceJanuary 30, 2025 | msn.comJoin Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5January 29, 2025 | globenewswire.comCalidi announces termination of standby equity purchase agreementJanuary 29, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase AgreementJanuary 28, 2025 | globenewswire.comCLDI stock touches 52-week low at $0.73 amid market challengesJanuary 22, 2025 | msn.comCalidi Biotherapeutics (NYSE American: CLDI) Prices $4.25 Million Public OfferingJanuary 13, 2025 | theglobeandmail.comCalidi to present new data on systemic virotherapy RTNova platformJanuary 13, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025January 13, 2025 | markets.businessinsider.comCalidi Biotherapeutics Prices Offering Of 5 Mln Shares At $0.85/Share, Stock FallsJanuary 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics slumps 29%, prices $4.25M stock offeringJanuary 10, 2025 | msn.comCalidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common StockJanuary 10, 2025 | globenewswire.comCalidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common StockJanuary 10, 2025 | globenewswire.comCalidi announces common stock offering, no amount givenJanuary 9, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Proposed Public OfferingJanuary 8, 2025 | globenewswire.comAllan Camaisa Sells 10,000 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) StockDecember 19, 2024 | insidertrades.comCalidi Biotherapeutics (NYSE American: CLDI) at the Forefront of Cancer Treatment InnovationDecember 13, 2024 | theglobeandmail.comCalidi Biotherapeutics prices $7.5M secondary offeringDecember 12, 2024 | msn.comCalidi Biotherapeutics (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer CareDecember 9, 2024 | theglobeandmail.comCalidi Biotherapeutics (NYSE American: CLDI) Showcases RTNova Virotherapy BreakthroughNovember 19, 2024 | theglobeandmail.comCalidi Biotherapeutics Reveals Promising Virotherapy DataNovember 18, 2024 | markets.businessinsider.comCalidi Biotherapeutics: Innovative Cancer Treatment with Promising Clinical Results but Financial ChallengesNovember 18, 2024 | markets.businessinsider.comCalidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung CancerNovember 18, 2024 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common StockNovember 15, 2024 | globenewswire.comCalidi prices 4.4M shares at $1.69 in public offeringNovember 14, 2024 | markets.businessinsider.comCalidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common StockNovember 14, 2024 | globenewswire.comCalidi Biotherapeutics Surges on 3Q Report, Retreats on Stock-Offer NewsNovember 14, 2024 | marketwatch.comCalidi Biotherapeutics Announces Proposed Public OfferingNovember 13, 2024 | globenewswire.comCalidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial ResultsNovember 12, 2024 | globenewswire.comCalidi Biotherapeutics’ (NYSE American: CLDI) Groundbreaking Cancer Treatment on RedChip’s Bloomberg TV ProgramOctober 29, 2024 | theglobeandmail.comCalidi Biotherapeutics (NYSE American: CLDI) to Present Antitumor Virotherapy Platform Data at ConferencesOctober 28, 2024 | theglobeandmail.comCalidi to present data supporting RTNova at upcoming conferencesOctober 25, 2024 | markets.businessinsider.com Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDI Media Mentions By Week CLDI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDI News Sentiment▼0.150.57▲Average Medical News Sentiment CLDI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDI Articles This Week▼21▲CLDI Articles Average Week Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ImmuCell News Today Sutro Biopharma News Today PDS Biotechnology News Today Cue Biopharma News Today CytomX Therapeutics News Today Medicus Pharma News Today Artiva Biotherapeutics News Today Citius Oncology News Today BeyondSpring News Today Acrivon Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CLDI) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLDI Stock Free CLDI Stock Alerts